CyTOF summit Agenda
An introduction to our educational and thought-provoking program, in which you will hear about applications, experimental design and data analysis approaches being applied by innovative investigators from academia, biotech and pharma with a focus on immuno-oncology.
Andrew Quong, PhD
Jonathan Irish, PhD
High-Content Cytometry Solutions for Investigation, Discovery and Therapeutic Development in Immuno-Oncology
A brief overview of the use of CyTOF® technology to date in immuno-oncology, as well as an introduction of the newest products offered by Standard BioTools that are particularly relevant for the immuno-oncology field.
Roberto Spada, PhD
Customization of the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ for Use in a Biotech Setting
Estrada discusses the significance of studying the proteome of single cells as a critical part of understanding and advancing immunotherapy studies and how the ease of customizing ready-to-use Standard BioTools immune profiling panels and workflows has sped time-to-answer for 2seventy bio.
Pedro Estrada, MS
Simultaneous Quantification of Multiple Targets With Mass Cytometry to Support Biotherapeutic Drug Development
Stevens introduces an approach for simultaneous analysis of multiple cell surface drug target receptors in diverse cell populations based on deep immunophenotyping of human whole blood samples. This technique is being used in biotherapeutic development to inform modeling and simulation teams on target feasibility and coverage requirements at Pfizer.
Chad Stevens, MS
Pfizer Worldwide Research & Development
Irish presents his latest work on glioblastoma, focusing on contrasting immune microenvironments seen in glioblastoma tumor types that can be detected on MRI. He discusses the use of CyTOF as a great technique for quantifying and characterizing all of the cells that are present in the tissue, including key navigation, T cell subtyping, activation and memory, checkpoint and life and death markers that allow measurement of what correlates with treatment responses or prognostic signatures.
Jonathan Irish, PhD
An Unsupervised Learning Approach to Quantifying T Cell States From High-Plex Cytometry Data in Cancer Immunotherapy Clinical Trials
Cytometric studies surveying cell phenotypes often do not account for functional states of immune cells that occur along continuous phenotypic transitions. To overcome this limitation, Sidiropoulos explains how he and his team have applied single-cell trajectory inference and non-negative matrix factorization methods to CyTOF data to trace the dynamics of T cell states.
Dimitrios Sidiropoulos, PhD Candidate
Johns Hopkins School of Medicine
Ihrie outlines how CyTOF has been particularly useful in dissecting the complex mix of cell types present in glioblastoma by enabling cell classification and how Imaging Mass Cytometry™ supports an understanding of cell interactions in the tumor microenvironment and furthers insights into the connection of tumor contact status with prognosis.
Rebecca Ihrie, PhD
Ramakrishna conducted a phase I trial (NCT02107963) to determine the feasibility of production and safety of administering escalating doses of GD2.Ox40.CD28.z chimeric antigen receptor T cells (GD2-CAR T) in children and young adults with neuroblastoma and osteosarcoma. She explains the robust GD2-CAR T expansion observed in half of the patients but limited persistence in all patients.
Sneha Ramakrishna, MD
Center for Cancer Cell Therapy, Stanford University School of Medicine
Panel members come together to jointly answer questions from the audience on their research and use of CyTOF technology in immuno-oncology. They discuss how they have collected and analyzed comprehensive CyTOF data and converted their analyses into clinically relevant insights.
Rebecca Ihrie, PhD
Have questions about CyTOF® related products?
We are here to help you!
Visit our Mass Cytometry page for more information.
Please submit the form below and we will get back to you as soon as possible.